γδ T-PD-1 Ab Cells in the Treatment of Advanced Solid Tumors

NCT06404281 | Recruiting Phase 1

• 1 other identifier: [2024]KY024-01
• Study Type: interventional
• Target: 9
• Locations: 1 country
• Sites: 1

Brief Summary

This study intends to combine the advantages of γδ T cells and PD-1 monoclonal antibody to conduct an exploratory clinical study on the safety and efficacy of PD-1 antibody armored γδ T cells (γδ T-PD-1 Ab cells) in the treatment of advanced solid tumors.

Conditions

Advanced Solid Tumor

Outcome Measures

Primary Outcomes (3)

• Safety evaluation: Incidence of Adverse events (AEs)

  Therapy-related adverse events will be recorded and assessed according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE, Version 5.0).

  up to 60 weeks

• Safety evaluation: Dose limited toxicity (DLTs)

  The incidence, characteristic and severity of DLTs will be recorded and assessed.

  up to 60 weeks

• Safety evaluation: Maximum-tolerated dose (MTD)

  MTD or clinical recommended dose will be recorded and evaluated.

  up to 60 weeks

Secondary Outcomes (4)

• Efficacy evaluation: Objective Response Rate(ORR)

  up to 15months

• Efficacy evaluation: Disease Control Rate (DCR)

  up to 15months

• Efficacy evaluation: Progress Free Survival(PFS)

  up to 15months

• Efficacy evaluation: Overall Survival (OS)

  up to 15months

Study Arms (1)

γδ T-PD-1 Ab cells

EXPERIMENTAL

Patients will receive 6 cycles of ex-vivo expanded γδ T-PD-1 Ab cells treatments,at two-weeks' intervals.γδ T-PD-1 Ab cells are transfused to patients in atypical 3+3 dose-escalation design(Dose escalation,3x10\^7/kg,1x10\^8/kg,3x10\^8/kg).

Biological: γδ T-PD-1 Ab cells

Interventions

γδ T-PD-1 Ab cells BIOLOGICAL

Cells will be extracted from a healthy donor, followed by ex-vivo expansion, activation and genetic engineering. The ex-vivo expanded γδ T-PD-1 Ab cells will be adoptively transfused to tumor patients.

γδ T-PD-1 Ab cells

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• The patient voluntarily signs the informed consent and can complete the follow-up examination, evaluation and treatment;
• Age 18-80 years old, gender is not limited;
• The histopathological diagnosis was malignant solid tumor;
• Clinical or pathological was stage IV according to AJCC 8th edition stage;
• Subjects with advanced solid tumors without standard treatment options;
• ECOG score 0-1;
• Expected survival ≥6 months;
• Have at least one evaluable lesion according to RECIST 1.1 criteria;
• Organ function level requirements (no blood transfusion or blood products, no hematopoietic stimulating factors, no albumin or blood products used within 14 days prior to the first dose);
• Bone marrow function: absolute value of neutrophils (ANC) ≥1.5×109, platelets ≥75×109, and hemoglobin (Hb) ≥90g/L;
• Liver function: total bilirubin ≤1.5 times the upper limit of normal (ULN); Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 times ULN (5.0 times ULN if liver metastasis is present), alkaline phosphatase \< 5 × ULN;
• Renal function: serum creatinine level ≤2 ULN, creatinine clearance \> 50mL/min (according to Cockcroft-Gault formula); Urine protein \<2+(If urine protein ≥2+, urine protein measurement should be collected for 24 hours, and the total amount should be \<1g to be allowed to enter the group);
• The serum pregnancy test of women of childbearing age in the 7 days prior to Gamma-delta T-PD-1 Ab infusion is negative, and any fertile male and female subject must consent to the use of an effective contraceptive method throughout the study and for at least 12 weeks after the last study administration. In the researchers' judgment, a subject is fertile: he/she is biologically capable of having children and having a normal sex life.
• A hysterectomy or bilateral oophorectomy has been performed, or ovarian failure has been medically confirmed, or post-menopause has been medically confirmed (menopause for at least 12 consecutive months without pathological or physiological causes).

You may not qualify if:

• Intolerance or allergy to any ingredient or similar drug in the treatment plan planned for this study;
• Metastasis of symptomatic central system;
• Have received other cell therapies, including NK, CIK, DC, CTL, CAR-T, TCR-T, and stem cell therapy in the past 4 weeks;
• Received systemic steroid therapy (\> 10 mg/kg prednisone or equivalent) or any other form of immunosuppressive medication within two weeks prior to the first dose; Corticosteroids (≤10mg oral prednisone or equivalent) were used in subjects with chronic obstructive pulmonary disease, saline corticosteroids (such as hydrohydrocortisone) were used in subjects with postural hypotension, and low-dose supplemental corticosteroids were used in subjects with adrenal insufficiency.
• Plan to use any other form of systemic antitumor therapy during the study period;
• History of known hematological malignancy, primary brain tumor or sarcoma, or other primary solid tumor within 6.5 years, unless cured and no evidence of recurrence of the disease within 5 years. With the exception of cured basal cell carcinoma of the skin and cervical carcinoma in situ;
• History of interstitial lung disease, non-infectious pneumonia or uncontrolled disease, including pulmonary fibrosis and acute lung disease;
• Active autoimmune diseases within the past 2 years requiring systemic treatment (such as glucocorticoids or immunosuppressive drugs), and related replacement therapy (such as thyroxine, insulin, or physiologic glucocorticoid replacement therapy for renal or pituitary insufficiency); Bisphosphonates were administered within 2 months prior to Γδ T-PD-1 Ab infusion.
• Known subjects had systemic vasculitis, co-active or uncontrolled autoimmune disease, primary or secondary immune deficiency, graft-versus-host disease (GvHD).
• Hepatitis B infection, hepatitis C infection, human immunodeficiency virus (HIV) infection, Treponema pallidum (TP) infection.
• Had undergone major surgery within 4 weeks prior to screening that was assessed by the investigator as unsuitable for enrollment.
• Acute infection and gastrointestinal bleeding occurred in 4 weeks.
• Major organ dysfunction: absolute value of neutrophils (ANC) \< 1.5×109, platelets \< 75×109, and hemoglobin (Hb) \< 90g/L; Serum albumin \< 28g/L, total bilirubin \>51μmol/L, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>5 times the upper limit of normal, creatinine \> 1.5 times the upper limit of normal; Have abnormal coagulation function (INR \> 1.5 or PT \>1.2 ULN or PTT \>1.2 ULN), have a tendency to bleed, or are receiving thrombolytic or anticoagulant therapy.
• People with a history of epilepsy or other active central nervous system diseases.
• Received live vaccine within 6 weeks prior to screening, and received hematopoietic stimulating factors, such as colony-stimulating factor and erythropoietin, within 2 weeks prior to treatment; Major surgical procedures (excluding diagnostic surgical procedures) within 4 weeks before the start of treatment;

Sponsors & Collaborators

• Changzhou No.2 People's Hospital: lead

Study Sites (1)

Changzhou No.2

Changzhou, China

RECRUITING

Study Officials

• Hua Jiang, MD

  Changzhou No.2 People's Hospital

  STUDY DIRECTOR

Central Study Contacts

Hua Jiang, MD

CONTACT

+86-18015852711; czeyjh@njmu.edu.cn

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Chief Director of Oncology Department

Study Record Dates

• First Submitted: April 21, 2024
• First Posted: May 8, 2024
• Study Start: August 1, 2024
• Primary Completion: January 1, 2026
• Study Completion (Estimated): June 1, 2026
• Last Updated: August 22, 2024

Record last verified: 2024-08

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)